Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Mitsuyasu

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
International Journal of Molecular Medicine|April 9, 2013
Efavirenz induces autophagy and aberrant differentiation in normal human keratinocytesQinghua Dong, Ju-Eun Oh, Jin Kyu Yi, et al.
AIDS (London, England)|February 6, 2009
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapyJack T Stapleton, Kathryn Chaloner, Jingyang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2021
Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 StudyLaura E Martínez, Shelly Lensing, Di Chang, et al.
Journal of Clinical Immunology|June 7, 2011
Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individualsRisa M Hoffman, Beth D Jamieson, Ronald J Bosch, et al.
Scientific Reports|June 2, 2022
Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHLLaura E Martínez, Shelly Lensing, Di Chang, et al.
Oncology|May 25, 2011
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysisSupriya Krishnan, Jeffrey T Schouten, Denise L Jacobson, et al.
Scientific Reports|July 11, 2025
CD20-bearing extracellular vesicles are associated with prognostic biomarkers of patients with AIDS-NHLLaura E Martínez, Shelly Lensing, Di Chang, et al.
AIDS (London, England)|August 16, 2013
Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkersÁlvaro H Borges, Michael J Silverberg, Deborah Wentworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2016
Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium TrialJoseph A Sparano, Jeannette Y Lee, Joel Palefsky, et al.
AIDS (London, England)|November 2, 2005
Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individualsHaydar Kuekrek, Tobias Schlingmann, Hernan Valdez, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
International Journal of Molecular Medicine|April 9, 2013
Efavirenz induces autophagy and aberrant differentiation in normal human keratinocytesQinghua Dong, Ju-Eun Oh, Jin Kyu Yi, et al.
AIDS (London, England)|February 6, 2009
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapyJack T Stapleton, Kathryn Chaloner, Jingyang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2021
Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 StudyLaura E Martínez, Shelly Lensing, Di Chang, et al.
Journal of Clinical Immunology|June 7, 2011
Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individualsRisa M Hoffman, Beth D Jamieson, Ronald J Bosch, et al.
Scientific Reports|June 2, 2022
Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHLLaura E Martínez, Shelly Lensing, Di Chang, et al.
Oncology|May 25, 2011
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysisSupriya Krishnan, Jeffrey T Schouten, Denise L Jacobson, et al.
Scientific Reports|July 11, 2025
CD20-bearing extracellular vesicles are associated with prognostic biomarkers of patients with AIDS-NHLLaura E Martínez, Shelly Lensing, Di Chang, et al.
AIDS (London, England)|August 16, 2013
Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkersÁlvaro H Borges, Michael J Silverberg, Deborah Wentworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2016
Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium TrialJoseph A Sparano, Jeannette Y Lee, Joel Palefsky, et al.
AIDS (London, England)|November 2, 2005
Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individualsHaydar Kuekrek, Tobias Schlingmann, Hernan Valdez, et al.
Pageof 5